These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

661 related items for PubMed ID: 20025693

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. The effects of anti-obesity intervention with orlistat and sibutramine on microvascular endothelial function.
    Al-Tahami BA, Ismail AA, Bee YT, Awang SA, Salha Wan Abdul Rani WR, Sanip Z, Rasool AH.
    Clin Hemorheol Microcirc; 2015; 59(4):323-34. PubMed ID: 24002121
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, Guvener N.
    Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
    [Abstract] [Full Text] [Related]

  • 47. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.
    Hendricks EJ, Greenway FL, Westman EC, Gupta AK.
    Obesity (Silver Spring); 2011 Dec; 19(12):2351-60. PubMed ID: 21527891
    [Abstract] [Full Text] [Related]

  • 48. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
    Padwal RS, Majumdar SR.
    Lancet; 2007 Jan 06; 369(9555):71-7. PubMed ID: 17208644
    [Abstract] [Full Text] [Related]

  • 49. Long term pharmacotherapy for obesity and overweight: updated meta-analysis.
    Rucker D, Padwal R, Li SK, Curioni C, Lau DC.
    BMJ; 2007 Dec 08; 335(7631):1194-9. PubMed ID: 18006966
    [Abstract] [Full Text] [Related]

  • 50. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J.
    Diabetes Obes Metab; 2000 Apr 08; 2(2):105-12. PubMed ID: 11220522
    [Abstract] [Full Text] [Related]

  • 51. Effect of orlistat-assisted weight loss on endothelium-dependent vasodilation in obese Chinese subjects with hypertension.
    Liu J, Sun N, Yang S, Ma Z, Yang J.
    Clin Exp Hypertens; 2010 Apr 08; 32(6):395-9. PubMed ID: 20804448
    [Abstract] [Full Text] [Related]

  • 52. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.
    Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J.
    Arch Intern Med; 2004 Jul 12; 164(13):1395-404. PubMed ID: 15249348
    [Abstract] [Full Text] [Related]

  • 53. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
    Kaukua JK, Pekkarinen TA, Rissanen AM.
    Int J Obes Relat Metab Disord; 2004 Apr 12; 28(4):600-5. PubMed ID: 14770192
    [Abstract] [Full Text] [Related]

  • 54. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
    O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G.
    Health Technol Assess; 2001 Apr 12; 5(18):1-81. PubMed ID: 11399238
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Effect of short-term administration of cinnamon on blood pressure in patients with prediabetes and type 2 diabetes.
    Akilen R, Pimlott Z, Tsiami A, Robinson N.
    Nutrition; 2013 Oct 12; 29(10):1192-6. PubMed ID: 23867208
    [Abstract] [Full Text] [Related]

  • 57. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.
    Douglas IJ, Bhaskaran K, Batterham RL, Smeeth L.
    Br J Clin Pharmacol; 2015 Jun 12; 79(6):1020-7. PubMed ID: 25641659
    [Abstract] [Full Text] [Related]

  • 58. Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
    Chaput JP, St-Pierre S, Tremblay A.
    Mini Rev Med Chem; 2007 Jan 12; 7(1):3-10. PubMed ID: 17266632
    [Abstract] [Full Text] [Related]

  • 59. Rimonabant for the treatment of overweight and obese people.
    Burch J, McKenna C, Palmer S, Norman G, Glanville J, Sculpher M, Woolacott N.
    Health Technol Assess; 2009 Oct 12; 13 Suppl 3():13-22. PubMed ID: 19846024
    [Abstract] [Full Text] [Related]

  • 60. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.
    Gursoy A, Erdogan MF, Cin MO, Cesur M, Baskal N.
    Eat Weight Disord; 2006 Dec 12; 11(4):e127-32. PubMed ID: 17272944
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.